Journal article

Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review

Vladica M Velickovic, Emily McIlwaine, Rongrong Zhang, Tim Spelman

Therapeutic Advances in Hematology | SAGE PUBLICATIONS LTD | Published : 2020


Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with an increased risk of graft-versus-host disease (GvHD), a strong prognostic predictor of early mortality within the first 2 years following allo-HSCT. The objective of this study was to describe the harm outcomes reported among patients receiving second- and third-line treatment as part of the management for GvHD via a systematic literature review. Methods: A total of 34 studies met the systematic review inclusion criteria, reporting adverse events (AEs) across 12 different second- and third-line therapies. Results: A total of 14 studies reported AEs across nine different therapies used in the treatm..

View full abstract


Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported with an unrestricted grant from Mallinckrodt Pharmaceuticals.